FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2940398384> ?p ?o ?g. }

• W2940398384 endingPage "A174" @default.
• W2940398384 startingPage "A173" @default.
• W2940398384 abstract "Lemborexant (LEM) is a dual-orexin-receptor antagonist under development for the treatment of insomnia and irregular sleep-wake rhythm disorder. As concerns regarding current sleep-promoting drugs include central respiratory depression (benzodiazepines) and limited safety evidence in vulnerable individuals such as the elderly (nonbenzodiazepine receptor agonists) and individuals with obstructive sleep apnea (OSA), it is important that LEM demonstrate safety in these groups. The primary objective of this study was to determine whether multiple LEM doses increased apnea-hypopnea index (AHI) in adult and elderly subjects with mild OSA versus placebo (PBO) using polysomnography (PSG). Secondary objectives included whether AHI increased and peripheral oxygen saturation (SpO2) decreased after single and multiple doses, and if SpO2 decreased below defined thresholds. This was a multicenter, multiple-dose, randomized, double-blind, PBO-controlled, 2-period crossover study in adult (age <65y) and elderly (age ≥65y) subjects with mild OSA (5≤AHI<15). Subjects were randomized to two 8-night treatment periods (separated by a washout ≥14d) with either LEM 10mg (LEM10) or PBO. In-lab PSG was performed at screening and on the first and last nights of both treatment periods. Thirty-nine subjects were randomized. The majority were White and female (61.5% each). Mean age was 57.2y; 66.7% were <65y and 33.3% were ≥65y. Mean baseline SpO2 (94.8%) and AHI (9.0) were comparable across treatment sequences. There was no significant difference in AHI (least squares mean) after single or multiple doses of LEM10 versus PBO (single: LEM10, 10.29; PBO, 10.22, P=0.979; multiple: LEM10, 9.93; PBO, 10.00, P=0.948). Similarly, there were no significant differences for LEM10 versus PBO in SpO2 after multiple or single doses (single: LEM10, 94.62%; PBO, 94.54%, P=0.699; multiple: LEM10, 94.65%; PBO, 94.39%, P=0.169), nor were there statistically significant differences from PBO for SpO2 below the thresholds of <90%, <85%, <80%, and for the presence of ≥1 incident of SpO2 <90% ≥30 seconds. LEM demonstrates respiratory safety with multiple and single dosing in adult and elderly subjects with mild OSA, as objectively measured by AHI and SpO2. Eisai Inc., Purdue Pharma L.P" @default.
• W2940398384 created "2019-04-25" @default.
• W2940398384 creator A5042782165 @default.
• W2940398384 creator A5059729118 @default.
• W2940398384 creator A5067561769 @default.
• W2940398384 creator A5078195357 @default.
• W2940398384 creator A5081572336 @default.
• W2940398384 creator A5090716271 @default.
• W2940398384 date "2019-04-01" @default.
• W2940398384 modified "2023-09-23" @default.
• W2940398384 title "0429 Respiratory Safety of Lemborexant in Adult and Elderly Subjects with Mild Obstructive Sleep Apnea" @default.
• W2940398384 doi "https://doi.org/10.1093/sleep/zsz067.428" @default.
• W2940398384 hasPublicationYear "2019" @default.
• W2940398384 type Work @default.
• W2940398384 sameAs 2940398384 @default.
• W2940398384 citedByCount "2" @default.
• W2940398384 countsByYear W29403983842020 @default.
• W2940398384 countsByYear W29403983842021 @default.
• W2940398384 crossrefType "journal-article" @default.
• W2940398384 hasAuthorship W2940398384A5042782165 @default.
• W2940398384 hasAuthorship W2940398384A5059729118 @default.
• W2940398384 hasAuthorship W2940398384A5067561769 @default.
• W2940398384 hasAuthorship W2940398384A5078195357 @default.
• W2940398384 hasAuthorship W2940398384A5081572336 @default.
• W2940398384 hasAuthorship W2940398384A5090716271 @default.
• W2940398384 hasBestOaLocation W29403983841 @default.
• W2940398384 hasConcept C126322002 @default.
• W2940398384 hasConcept C142724271 @default.
• W2940398384 hasConcept C168563851 @default.
• W2940398384 hasConcept C204787440 @default.
• W2940398384 hasConcept C27081682 @default.
• W2940398384 hasConcept C2776006263 @default.
• W2940398384 hasConcept C2778205975 @default.
• W2940398384 hasConcept C2781326671 @default.
• W2940398384 hasConcept C42219234 @default.
• W2940398384 hasConcept C71924100 @default.
• W2940398384 hasConceptScore W2940398384C126322002 @default.
• W2940398384 hasConceptScore W2940398384C142724271 @default.
• W2940398384 hasConceptScore W2940398384C168563851 @default.
• W2940398384 hasConceptScore W2940398384C204787440 @default.
• W2940398384 hasConceptScore W2940398384C27081682 @default.
• W2940398384 hasConceptScore W2940398384C2776006263 @default.
• W2940398384 hasConceptScore W2940398384C2778205975 @default.
• W2940398384 hasConceptScore W2940398384C2781326671 @default.
• W2940398384 hasConceptScore W2940398384C42219234 @default.
• W2940398384 hasConceptScore W2940398384C71924100 @default.
• W2940398384 hasIssue "Supplement_1" @default.
• W2940398384 hasLocation W29403983841 @default.
• W2940398384 hasOpenAccess W2940398384 @default.
• W2940398384 hasPrimaryLocation W29403983841 @default.
• W2940398384 hasRelatedWork W2016370421 @default.
• W2940398384 hasRelatedWork W2086465337 @default.
• W2940398384 hasRelatedWork W2165614801 @default.
• W2940398384 hasRelatedWork W2186303850 @default.
• W2940398384 hasRelatedWork W2383496458 @default.
• W2940398384 hasRelatedWork W2385244159 @default.
• W2940398384 hasRelatedWork W2385652705 @default.
• W2940398384 hasRelatedWork W2605291975 @default.
• W2940398384 hasRelatedWork W2783011192 @default.
• W2940398384 hasRelatedWork W2598067411 @default.
• W2940398384 hasVolume "42" @default.
• W2940398384 isParatext "false" @default.
• W2940398384 isRetracted "false" @default.
• W2940398384 magId "2940398384" @default.
• W2940398384 workType "article" @default.